ווטריינט 200 מ"ג

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

PAZOPANIB AS HYDROCHLORIDE 200 MG

Verfügbar ab:

GLAXO SMITH KLINE (ISRAEL) LTD

ATC-Code:

L01XE11

Darreichungsform:

FILM COATED TABLETS

Verabreichungsweg:

PER OS

Hergestellt von:

GLAXO OPERATIONS UK LIMITED

Therapiegruppe:

PAZOPANIB

Anwendungsgebiete:

Renal cell carcinoma (RCC)Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Berechtigungsdatum:

2011-01-01